Triglyceride-Glucose Index is Significantly Associated with the Risk of Hyperuricemia in Patients with Nonalcoholic Fatty Liver Disease

Figures & data

Table 1 Demographic and Clinical Characteristics of Participants by the Presence of HUA

	HUA (166)	Non-HUA (295)	P
Age (years)	55.23±10.89	57.77±9.86	0.011
Gender (Male)	106 (63.9)	165 (55.9)	0.097
Smoke[(n%)]	70(42.2)	125(42.4)	0.966
HTN[(n%)]	97(58.4)	158(53.6)	0.312
DM[(n%)]	48(28.9)	90(30.5)	0.720
MetS[(n%)]	70(42.2)	110(37.3)	0.303
BMI (kg/M2)	26.36±2.81	25.77±2.77	0.032
SBP (mmHg)	126.69±19.37	129.93±17.92	0.071
DBP (mmHg)	76.55±13.14	75.56±12.83	0.430
ALT(U/L)	27.65 (18.48, 40.93)	23.00 (16.00, 35.20)	0.004
AST(U/L)	25.10 (20.35, 37.25)	22.30 (18.10, 28.90)	<0.001
Scr(μmol/L)	72.00 (61.00, 81.25)	63.00 (54.00, 73.00)	<0.001
TC (mmol/L)	4.69 (3.87, 5.33)	4.37 (3.58, 5.26)	0.015
TG (mmol/L)	1.97 (1.32, 3.12)	1.69 (1.23, 2.31)	0.001
HDL-C(mmol/L)	1.07 (0.92, 1.24)	1.12 (0.96, 1.32)	0.014
LDL-C(mmol/L)	2.46 (2.11, 2.95)	2.34 (1.81, 2.85)	0.008
FPG (mmol/L)	5.61 (5.05, 6.48)	5.39 (4.80, 6.67)	0.127
TyG	9.14(8.70, 9.71)	8.88(8.59, 9.26)	0.001
TyG-BMI	244.38(221.90, 266.10)	230.25(210.61, 250.00)	<0.001

Notes: Values are expressed as mean ± standard deviation, no. (%), or median (interquartile range). P < 0.05 (two-sided) was defined as statistically significant.

Abbreviations: BMI, body mass index; HTN, hypertension diabetes mellitus; Mets, metabolic syndrome; SBP, systolic blood pressure; DBP, diastolic blood pressure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Scr, serum creatinine; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FPG, fasting plasma glucose; TyG, triglyceride-glucose index; TyG-BMI, TyG index with body mass index.

Figure 1 TyG level of patients in HUA group and non-HUA group.

Table 2 Univariate and Multivariate Logistic Regression Assesses the Correlation Between TyG and the Prevalence of HUA

	No-Adjust		Model 1		Model 2
	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
TyG	1.96(1.45–2.65)	<0.001	1.88(1.39–2.55)	<0.001	2.00(1.38–2.91)	<0.001
TyG 1	Ref.		Ref.		Ref.
TyG 2	1.09(0.67–1.78)	0.735	1.10(0.67–1.81)	0.696	1.13(0.67–1.92)	0.650
TyG 3	2.32(1.45–3.72)	<0.001	2.23(1.39–3.60)	<0.001	2.11(1.21–3.68)	0.008
P for trend	P<0.001

Notes: None, non-adjusted model; Model I was adjusted for age and sex; Model II was adjusted for age, sex, BMI, HTN, DM, smoking history, ALT, AST and Scr.

Figure 2 Prevalence of hyperuricemia in NAFLD patients with different TyG quantiles.

Figure 3 The association between TyG index and hyperuricemia was shown using restricted cubic splines with three segments of the 10th, 50th and 90th percentiles of TyG index, adjusting for age, sex, BMI, hypertension, diabetes mellitus, smoking history, ALT, AST and Scr.

Figure 4 Subgroup analysis of association between TyG and hyperuricemia, adjusted for age, sex, BMI, hypertension, diabetes, smoking history, ALT, AST, and Scr, excluding grouping variables.

Figure 5 ROC curve analysis of the predictive power of TyG for HUA.

Table 3 Univariate and Multivariate Linear Regression of Uric Acid

	No-Adjust			Adjusted
	β	95% CI	P	β	95% CI	P
TyG*0.1	1.53	0.87–2.18	<0.001	1.37	0.67–2.08	<0.001

Notes: Adjusted model was composed of age, sex, BMI, HTN, DM, smoking history, ALT, AST and Scr.

Figure 6 The correlation between TyG index and uric acid.